Fluciclovine F18 (Axumin) has been demonstrated to provide good delineation of recurrence of
prostate cancer after definitive therapies. Fluciclovine in conjunction with the
high-resolution digital Vereos (Phillips) PET-CT scanner may detect low volume recurrence in
the prostatectomy bed or metastatic site (s).
20-40 % of men will suffer a biochemical recurrence of their prostate cancer after radical
prostatectomy, depending on their final pathological staging, defined as a rising PSA > 0.2
ng/ml.
The ability to more accurately diagnose local recurrence (i.e. pelvis) or oligometastasis may
lead to the opportunity of precise therapy of these sites with more durable cancer responses,
less morbidity and potential cure in selective men after Radical Prostatectomy.
The ability to diagnose widespread metastatic Prostate Cancer after Radical Prostatectomy, or
disease that is inaccessible to local selective therapies would spare these men the cost and
morbidity of inappropriate therapy.
The diagnosis of true stage D0 Prostate Cancer (No objective evidence of metastases) in men
after Radical Prostatectomy would yield improved overall and disease specific survival if
Androgen Deprivation Therapy was initiated at its earliest stage. This would also obviate the
need for inappropriate local therapies (i.e. pelvic radiotherapy).
The aim is to compare the detection rate of standard of care (CT Pelvis/Abdomen, MR Pelvis,
Bone Scan) with Fluciclovine PET/CT performed on the Vereos Philips Scanner. The study aims
to compare the performance of Digital (high resolution) PET to CT/MRI/Bone scan rather than
analog (lower resolution) PET. Prior studies have tested analog PET compared to other
modalities. One could make an inference that if our study's Digital PET performs better than
the performance of Analog PET in those studies, then Digital PET should have a better
detection rate than Analog PET. However, investigators are not making a direct comparison
between digital and Analog in our comparison.